Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
AURA

Aura Biosciences, Inc.

AURA

NASDAQ·Healthcare·Biotechnology·Mkt cap $782.0M

$7.56

▲ +2.58%

P/E

-4.25

Mkt Cap

$782.0M

52-Wk Range

$4.73–$9.54

52-Week Range

$4.73 - $9.54

P/E

-4.25

Fwd P/E

-4.54

Beta

0.40

Div Yield

0.00%

Avg Vol

685.4K

Shares Out

64.2M

Mkt Cap

$782.0M

Price action

Price chart

Up 16.9% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary VDC technology platform enabling targeted drug delivery with reduced systemic toxicity
  • First-mover advantage in virus-like drug conjugate approach for ocular and urologic cancers
  • Focus on high unmet need indications with limited competitive landscape and potential for accelerated regulatory approval
  • Specialized expertise in rare and orphan oncology indications with premium pricing potential
▼

Bear Case

1 risk

  • Low volatility (beta 0.4).

Growth

Stable outlook

AU-011 clinical trial progression and potential FDA approval for choroidal melanoma and metastases

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Strong

+16.7% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 5, 2026

“
Q3 26 RECAP

AUG 11, 2026

Reported EPS of -$0.48 vs -$0.38 consensus (-28.0% surprise).

EPS miss

EPS surprise · last 4Q

0 of 1 beats

Estimate

Actual

Q3 26

-28.0%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

1 analyst · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

1

100%

Hold

0%

Sell

0%

Median Price Target

—

Latest: HC Wainwright · Aug 12, 2026

View full analyst page →

vs Industry

How AURA stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.